Your browser is no longer supported. Please, upgrade your browser.
Vyant Bio, Inc.
Index- P/E- EPS (ttm)-3.67 Insider Own2.40% Shs Outstand28.99M Perf Week-17.65%
Market Cap53.10M Forward P/E- EPS next Y-0.08 Insider Trans9.04% Shs Float25.87M Perf Month-40.21%
Income-19.80M PEG- EPS next Q- Inst Own10.20% Short Float0.40% Perf Quarter-36.60%
Sales5.00M P/S10.62 EPS this Y11.00% Inst Trans0.34% Short Ratio0.96 Perf Half Y-58.10%
Book/sh1.93 P/B0.87 EPS next Y- ROA-38.20% Target Price5.00 Perf Year-31.71%
Cash/sh0.73 P/C2.29 EPS next 5Y40.00% ROE-43.00% 52W Range1.72 - 17.50 Perf YTD-39.35%
Dividend- P/FCF- EPS past 5Y44.20% ROI-199.60% 52W High-90.40% Beta2.25
Dividend %- Quick Ratio5.50 Sales past 5Y-20.40% Gross Margin14.30% 52W Low-2.33% ATR0.15
Employees40 Current Ratio5.60 Sales Q/Q-6.30% Oper. Margin- RSI (14)26.80 Volatility7.20% 6.39%
OptionableNo Debt/Eq0.00 EPS Q/Q73.50% Profit Margin- Rel Volume1.23 Prev Close1.83
ShortableYes LT Debt/Eq0.00 EarningsNov 11 AMC Payout- Avg Volume106.59K Price1.68
Recom3.00 SMA20-24.55% SMA50-25.91% SMA200-50.50% Volume131,080 Change-8.20%
Nov-29-21 09:15AM  
Nov-11-21 04:00PM  
Nov-10-21 04:15PM  
Nov-09-21 09:15AM  
Oct-26-21 08:00AM  
Oct-19-21 08:30AM  
Oct-08-21 11:31AM  
Sep-09-21 08:00AM  
Aug-19-21 09:27AM  
Aug-16-21 04:01PM  
Aug-11-21 09:00AM  
Jul-27-21 08:30AM  
Jul-13-21 08:20AM  
May-18-21 06:45AM  
May-17-21 05:15PM  
May-13-21 08:00AM  
May-11-21 04:36PM  
Apr-22-21 08:00AM  
Apr-05-21 04:20PM  
Apr-01-21 05:45PM  
Vyant Bio, Inc. operates as a biotechnology drug discovery company. The company, through its subsidiary, StemoniX, develops and manufactures at-scale human induced pluripotent stem (iPS) cell-derived neural and cardiac screening platforms for drug discovery and development. StemoniX, through collaborations with drug discovery organizations, tests compounds in-house, creates cell-based disease models, and operationalizes custom human iPSC-derived disease models for high-throughput screening. The company, through its subsidiary, vivoPharm, offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages by the pharmaceutical industry, biotechnology companies, and academic research centers. vivoPharm specializes in conducting studies to guide drug development, starting from compound libraries and ending with a set of in vitro and in vivo data and reports, as needed for investigational new drug filings. The company is based in Cherry Hill, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROBERTS JOHN AChief Executive OfficerNov 24Buy2.025,00010,10039,807Nov 24 04:05 PM
LaFrence Andrew D.C.Chief Financial OfficerNov 23Buy2.005,0009,99834,336Nov 24 04:05 PM
Yeh Yung-PingChief Innovation OfficerNov 22Buy2.055001,02512,762Nov 23 07:51 PM
Fremeau Robert Thomas Jr.Chief Scientific OfficerOct 28Buy2.191,0002,1901,000Nov 17 05:05 PM
Boehm MarcusDirectorOct 27Buy2.105,00010,500123,786Oct 28 04:30 PM
Boehm MarcusDirectorSep 29Buy2.445,00012,200118,786Sep 30 08:45 AM
Yeh Yung-PingChief Innovation OfficerAug 25Buy2.641,0002,64012,262Aug 27 08:45 AM
Boehm MarcusDirectorAug 25Buy2.585,00012,878113,786Aug 26 08:45 AM
ROBERTS JOHN AChief Executive OfficerAug 23Buy2.4110,40625,07834,807Aug 25 05:03 PM
Hansen Paul R.DirectorAug 19Buy2.3520,00047,000617,957Aug 23 03:42 PM
Boehm MarcusDirectorJul 28Buy2.925,00014,624108,786Jul 28 09:45 PM
Boehm MarcusDirectorMay 28Buy3.685,00018,40098,929Jun 01 05:10 PM
ROBERTS JOHN AChief Executive OfficerMay 26Buy3.557,04124,996312,117May 27 05:31 PM
FLETCHER R JOHNDirectorMay 24Buy3.3915,30051,83530,300May 24 04:05 PM
ROBERTS JOHN AChief Executive OfficerMay 24Buy3.387,44025,147305,076May 27 05:31 PM
FLETCHER R JOHNDirectorMay 21Buy3.3315,00049,94815,000May 24 04:05 PM
Yeh Yung-PingChief Innovation OfficerMay 20Buy3.291,0003,2901,329,602May 21 04:05 PM
LaFrence Andrew D.C.Chief Financial OfficerMay 20Buy3.283,0009,83732,336May 21 04:05 PM